Literature DB >> 22432888

Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

Paul K L Chin1, Jane W A Vella-Brincat, Murray L Barclay, Evan J Begg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22432888      PMCID： PMC3495137          DOI： 10.1111/j.1365-2125.2012.04266.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  21 in total

1.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

2.  Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.

Authors:  Thorsten Lehr; Sebastian Haertter; Karl-Heinz Liesenfeld; Alexander Staab; Andreas Clemens; Paul A Reilly; Jeffrey Friedman
Journal:  J Clin Pharmacol       Date:  2011-09-28       Impact factor: 3.126

3.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

4.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

5.  Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Authors:  Joachim Stangier; Hildegard Stähle; Karin Rathgen; Reinhold Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.

Authors:  Stefan Blech; Thomas Ebner; Eva Ludwig-Schwellinger; Joachim Stangier; Willy Roth
Journal:  Drug Metab Dispos       Date:  2007-11-15       Impact factor: 3.922

7.  Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

Authors:  Jeffrey S Ginsberg; Bruce L Davidson; Philip C Comp; Charles W Francis; Richard J Friedman; Michael H Huo; Jay R Lieberman; James E Muntz; Gary E Raskob; Mary L Clements; Stefan Hantel; Janet M Schnee; Joseph A Caprini
Journal:  J Arthroplasty       Date:  2008-04-14       Impact factor: 4.757

8.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Authors:  Bengt I Eriksson; Ola E Dahl; Nadia Rosencher; Andreas A Kurth; C Niek van Dijk; Simon P Frostick; Martin H Prins; Rohan Hettiarachchi; Stefan Hantel; Janet Schnee; Harry R Büller
Journal:  Lancet       Date:  2007-09-15       Impact factor: 79.321

Review 9.  Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

Authors:  Joachim Stangier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335
View more
  8 in total

1.  Optimizing the dose of dabigatran etexilate.

Authors:  John Posner
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Editors' pick 2012.

Authors:  Lionel D Lewis; Andrew Somogyi; Yoon K Loke; Albert Ferro; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.

Authors:  Paul K L Chin; David M Patterson; Mei Zhang; Berit P Jensen; Daniel F B Wright; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

4.  Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.

Authors:  Paul K L Chin; Daniel F B Wright; Mei Zhang; Mary C Wallace; Rebecca L Roberts; David M Patterson; Berit P Jensen; Murray L Barclay; Evan J Begg
Journal:  Drugs R D       Date:  2014-06

Review 5.  A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.

Authors:  Paul K L Chin; Daniel F B Wright; David M Patterson; Matthew P Doogue; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

6.  Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.

Authors:  Luigi Brunetti; Betty Sanchez-Catanese; Leonid Kagan; Xia Wen; Min Liu; Brian Buckley; James P Luyendyk; Lauren M Aleksunes
Journal:  Thromb J       Date:  2016-05-06

7.  Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly.

Authors:  Anders Helldén; Ingegerd Odar-Cederlöf; Göran Nilsson; Susanne Sjöviker; Anders Söderström; Mia von Euler; Gunnar Ohlén; Ulf Bergman
Journal:  BMJ Open       Date:  2013-04-11       Impact factor: 2.692

8.  Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling.

Authors:  Nan Wang; Lu Chen; Na Li; Gaoqi Xu; Fang Qi; Liqin Zhu; Wensheng Liu
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.